|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Belongs to our Healthcare sector and Medium P/E group with a P/E of 23,32.
The stocks were selected based on their earnings, growth potential and risk of financial distress. These factors were determined by the company’s P/E-ratios, growth estimates and the strength of their financial positions.
Growth company, operating in expanding field of biotechnology. Financials are believed to be growing according to Yahoo Finance's trailing twelve month numbers, but stock price has not reacted yet. Relatively low beta (0,79) Stock is believed to be undervalued (Yahoo Finance), so there could be returns available with low risk.
Vertex Pharmaceuticals inc. Short position Constructing our initial portfolio The firm's price has recently dropped close to its 52-week low so according to our 52-week high/low momentum investment strategy, we expect the firm to be decreasing in value further in the near future due to the negative momentum it is experiencing. (Aiming for 1.8 leverage ratio)